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Abstract
Background: Various individual biomarkers of inflammation and micronutrient status, often correlated with each
other, are associated with adverse treatment outcomes in human immunodeficiency virus (HIV)-infected adults. The
objective of this study was to conduct exploratory factor analysis (EFA) on multiple inflammation and micronutrient
biomarkers to identify biomarker groupings (factors) and determine their association with HIV clinical treatment
failure (CTF) and incident active tuberculosis (TB).
Methods: Within a multicountry randomized trial of antiretroviral therapy (ART) efficacy (PEARLS) among HIV-infected
adults, we nested a case-control study (n = 290; 124 cases, 166 controls) to identify underlying factors, based on EFA of
23 baseline (pre-ART) biomarkers of inflammation and micronutrient status. The EFA biomarker groupings results were
used in Cox proportional hazards models to study the association with CTF (primary analysis where cases were incident
World Health Organization stage 3, 4 or death by 96 weeks of ART) or incident active TB (secondary analysis).
Results: In the primary analysis, based on eigenvalues> 1 in the EFA, three factors were extracted: (1) carotenoids), (2)
other nutrients, and (3) inflammation. In multivariable-adjusted models, there was an increased hazard of CTF (adjusted
hazard ratio (aHR) 1.47, 95% confidence interval (CI)1.17–1.84) per unit increase of inflammation factor score. In the
secondary incident active TB case-control analysis, higher scores of the high carotenoids and low interleukin-18 factor
was protective against incident active TB (aHR 0.48, 95% CI 0.26–0.87).
Conclusion: Factors identified through EFA were associated with adverse outcomes in HIV-infected individuals.
Strategies focused on reducing adverse HIV outcomes through therapeutic interventions that target the underlying
factor (e.g., inflammation) rather than focusing on an individual observed biomarker might be more effective and
warrant further investigation.
Keywords: HIV, Inflammation, Antiretroviral therapy, Tuberculosis, IL-18, Exploratory factor analysis
* Correspondence: rs3895@cumc.columbia.edu
1Department of Medicine, Johns Hopkins University School of Medicine,
Baltimore, MD, USA
17Present Address: Department of Epidemiology, Columbia University
Mailman School of Public Health, 722 West 168th St, Room 705, New York,
NY 10032, USA
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Shivakoti et al. BMC Medicine  (2018) 16:161 
https://doi.org/10.1186/s12916-018-1150-3
Background
Single biomarkers have been assessed in antiretroviral
therapy (ART)-naïve HIV-infected adults in multiple
studies, and results show that specific biomarkers of
inflammation or micronutrient concentrations are asso-
ciated with adverse outcomes [1–4]. Various markers of
inflammation, including C-reactive protein (CRP),
soluble CD14 (sCD14), and various cytokines (e.g.,
interleukin-6 and 18 (IL-6 and IL-18)), are associated
with increased mortality and morbidity [1–6]. Morbidity
includes increased clinical treatment failure (CTF), risk
of incident active TB, and even longer-term outcomes
such as cardiovascular disease. Similarly, studies have
shown that levels of various micronutrients such as vita-
min D, selenium, and iron can also affect various HIV
outcomes [7–11].
However, many of the inflammation markers are corre-
lated with each other, such as in cases where they might be
activated by the same stimuli or signaling pathway [12]. The
nutritional biomarkers might also correlate with each other,
for example, if different micronutrients are part of the same
or similar foods [13]. Furthermore, there is evidence that in-
flammation and micronutrient status can directly affect each
other. For example, studies show that circulating levels of
selenium and zinc are reduced during the acute phase re-
sponse [14, 15]. As a result, studies on the association of
these biomarkers with outcomes might benefit from consid-
ering the relationship between these biomarkers.
Data reduction methods, such as exploratory factor ana-
lysis (EFA), have been useful in dealing with multicolli-
nearity [16]. EFA is a statistical method for data reduction,
in which numerous observed variables (e.g., circulating
biomarkers) that co-vary with each other are assumed to
reflect a smaller number of underlying unobserved vari-
ables (“factors”) [17]. An important point to note for these
analyses is that each individual will receive a score for
each factor (i.e., an individual whose pattern poorly
matches the factor gets a lower score), and the association
of a specific factor with an outcome is compared between
individuals with high and low scores of that factor, rather
than between different factors.
Various studies have shown that factor analysis can
identify biologically meaningful “biomarker superfam-
ilies” which can be utilized to stratify individuals in high-
and low-risk subgroups [12, 18–20] based on their factor
score and potentially identify therapeutics that target the
underlying factor rather than the individual observed
variables. An example of the public health potential for
EFA is evident in the field of nutrition and obesity where
dietary patterns (e.g., high fat/low fiber pattern) are iden-
tified based on EFA and are part of the intervention
(e.g., to consume less of that pattern) [21, 22].
The goal of this study was to conduct EFA on multiple
observed biomarkers of inflammation and micronutrient
status in HIV-infected adults initiating ART, in order to
identify biomarker groupings that are hypothesized to
represent underlying biological processes (factors) and
to determine whether these factors were associated with
adverse HIV outcomes including CTF (CTF as primary
outcome) and incident active tuberculosis (TB) (TB as
secondary outcome). To address this research question,
we conducted nested case-control studies within a mul-
ticountry randomized clinical trial of ART efficacy
(PEARLS) [23].
Methods
Study design and population
PEARLS was conducted from 2005 to 2010 (NCT00084136)
[23] in 1571 ART-naïve HIV-infected adults from diverse set-
tings to compare the efficacy of three different ART regi-
mens: (1) efavirenz plus twice-daily lamivudine-zidovudine;
(2) atazanavir plus didanosine EC and emtricitabine, all given
once daily; or (3) efavirenz plus emtricitabine-tenofovir DF
once daily. The primary efficacy outcome was treatment fail-
ure. PEARLS trial participants who met the inclusion criteria
(including age greater than 18 years old and CD4+ T cell
count less than 300 cells/mm3) were recruited from nine
different countries: Brazil (n= 231), Haiti (n = 100), India
(n = 255), Malawi (n = 221), Peru (n = 134), South Africa
(n = 210), Thailand (n = 100), the USA (n = 210), and
Zimbabwe (n = 110). Pregnant women and individuals with
an acute illness or severe anemia were excluded from the
study. Detailed inclusion and exclusion criteria for PEARLS
are described elsewhere [23].
For this study, we nested a case-control analysis (n = 290;
124 cases, 166 controls) within PEARLS to assess the associ-
ation of baseline (pre-ART initiation) biomarkers of inflam-
mation and micronutrients with CTF. CTF was defined as
an incident World Health Organization (WHO) stage 3 or 4
event (including incident activeTB) or death within 96 weeks
post-ART initiation [24]. While all the cases from the parent
study with available biomarker values were selected, controls
(who did not develop clinical failure by 96 weeks) were se-
lected based on random subsampling of the parent cohort
stratified by country (the same approach used for secondary
case controls).
Three other secondary nested case-control analyses
were performed: severe outcome case control (N = 254;
81 cases and 173 controls), virologic failure case control
(N = 260; 90 cases and 170 controls), and incident active
TB case control (N = 220; 47 cases and 173 controls)
analyses. The outcomes analyzed for these case controls
were (1) severe outcomes defined as death, serious bac-
terial infections or sepsis, and opportunistic infections
(including TB), (2) virologic failure defined as HIV-1
RNA levels ≥ 1000 copies/mL for two successive visits at
≥ 16 weeks after ART initiation, and (3) incident active
TB defined as pulmonary or extrapulmonary TB that
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developed during the follow-up period (96 weeks
post-ART initiation). We use the term “incident active
TB” to define anyone who presented with signs or symp-
toms of TB disease and resulted in having confirmed or
probable TB disease after entry into the study; the term
does not distinguish between recently acquired TB
through transmission, reactivation of TB, and subclin-
ical/unmasked TB. Using standardized AIDS Clinical
Trials Group (ACTG) definitions, incident active TB was
defined as one of the following: confirmed pulmonary
TB, probable pulmonary TB, confirmed extrapulmonary
TB, probable extrapulmonary TB, and TB immune re-
constitution inflammatory syndrome (TB-IRIS). While
the diagnostic information is described in detail else-
where [6], cases were considered confirmed if TB was
isolated by culture, and they were considered probable
based on signs and symptoms, acid-fast bacilli stain,
x-rays, and TB treatment initiation. The definitions were
standardized across the various sites, and the data for
each diagnosis were reviewed by five physicians in the
study team.
Data collection and laboratory analysis
Clinical history, including outcome assessment, was col-
lected at baseline and at 2, 4, and 8 weeks post-ART initi-
ation. After 8 weeks, clinical history was collected every
4 weeks through 24 weeks and every 8 weeks after that
through 96 weeks. Plasma and serum samples were col-
lected at baseline and other relevant time points and
stored at − 80 °C.
The exposure variables (23 markers of inflammation
and micronutrient status) were measured from plasma
and serum samples collected at baseline (pre-ART initi-
ation). Inflammation markers assessed in this study were
interferon-γ (IFN-γ), IL-6, IFN-γ inducible protein
(IP)-10, IL-18, tumor necrosis factor-α (TNF-α), CRP,
sCD14, and EndoCAb immunoglobulin M (IgM). Lumi-
nex multiplex enzyme-linked immunosorbent assays
(ELISAs) (R&D Systems, Minneapolis, MN, USA) were
used to measure plasma levels of IFN-γ, IL-6, and
TNF-α, while IP-10 was measured by MSD multiplex
ELISAs (Meso Scale Discovery, Rockville, MD, USA).
Single-plex ELISAs were used to measure plasma CRP,
sCD14 (both R&D Systems), IL-18 (eBiosciences), and
EndoCAb IgM (Cell Sciences, Canton, MA, USA). Fur-
ther details on the inflammation markers are described
elsewhere [6, 25].
The micronutrient markers assessed in this study were
markers of vitamin A (retinol), vitamin B6, vitamin B12,
vitamin D, vitamin E (α-tocopherol and γ-tocopherol),
iron (ferritin and soluble transferrin receptor), selenium,
and various carotenoids (α-carotene, β-carotene,
β-cryptoxanthin, lutein, lycopene, and zeaxanthin). De-
tails of assessment are described elsewhere [26]. Briefly,
serum ferritin (ALPCO, Salem, NH, USA) and soluble
transferrin receptor (R&D Systems) were measured
using an ELISA, while radioimmunoassay (DiaSorin,
Saluggia, Italy) was used to measure total (D2 and D3)
serum 25-hydoxyvitamin. High-performance liquid chro-
matography (HPLC) was used to measure serum vitamin
B6, retinol (vitamin A), and the carotenoids, as previously
described [26]. Abbott AxSYM (Abbott Laboratories, Lake
Bluff, IL, USA), an automated immunochemical analyzer,
was used to measure serum vitamin B12, while serum
selenium was assessed with a Perkins-Elmer AAnalyst 600
graphite furnace atomic absorption spectrometer.
Potential confounders measured at baseline and in-
cluded in multivariable models were body mass index
(BMI), CD4+ T cell count, plasma HIV RNA, hemoglobin,
and albumin. Plasma HIV-1 RNA was measured using the
Roche Amplicor Monitor Assay (v1.5; Roche Molecular
Systems, Branchburg, NJ, USA). Serum hemoglobin, albu-
min, and CD4+ T cell count were measured in the individ-
ual site laboratories that met the quality assurance
standards of the NIH ACTG Network laboratory [23].
Statistical analyses
Twenty-three immune and micronutrient biomarkers
were used to perform EFA, and the principal factor
method was used, which is the default factor analysis
method utilized by STATA software. In the principal fac-
tor method, the factor loadings are calculated using
squared multiple correlations. While we also considered
the proportion of variance explained, the final numbers
of factors were extracted based on scree plots and eigen-
values (number of observed variables which the factor
represents) greater than 1, as commonly done in EFA
studies [27]. For simpler interpretation, factors were
treated as orthogonal (where it is assumed that the fac-
tors themselves are not correlated to each other) and
were rotated through the varimax method, which im-
proves interpretability of orthogonal factors by rotating
the axes so that each observed variable will load strongly
on one of the factors [12]. Factor loadings above 0.3
were considered significant [28]; loadings are regression
coefficients that describe the relationship between an
unmeasured variable (i.e., an underlying factor which is
not directly measured) and an observed/measured bio-
marker (a similar idea to correlation but not the same).
The common characteristics among the high loading
biomarkers for each factor were used for interpreting
and naming the factors.
Based on the EFA, factor scores were generated for
each participant, with higher scores indicating a higher
standing in the scale (i.e., a better match to that factor).
The factor scores of the individuals were used in univari-
able and multivariable Cox proportional hazard models
to determine the association of each factor with outcome
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(CTF, severe outcomes, or TB). Sex, age, country, BMI,
baseline TB status, CD4 count, viral load, treatment arm
(ART regimen), anemia, and hypoalbuminemia were ad-
justed for in multivariable models. Baseline TB status is
a binary variable referring to prior (i.e., the patient had
TB disease and TB treatment prior to study initiation)
or prevalent TB (i.e., under TB treatment at baseline).
Race was not used in multivariable models due to
co-linearity with country. STATA version 13 was used
for data analysis.
Note that although the source population for the se-
vere outcomes and TB case controls was the same
PEARLS study as for the CTF case control, the specific
study population for each case control is different (due
to the different case definitions). As a result, although
factors are extracted independent of the outcome, the
different case controls themselves could have different
factor profiles since each case control has a different
sample population.
Results
Study population characteristics
The baseline characteristics of the cases and controls
in the CTF case-control population differed signifi-
cantly by the following baseline characteristics: coun-
try (p = 0.001), BMI (p = 0.001), prior TB diagnosis
(p = 0.01), CD4 T cell count, hypoalbuminemia, and
anemia (p < 0.001 for all) (Table 1).
EFA and association with clinical treatment failure
From the CTF case-control EFA analysis, three under-
lying factors (Additional file 1: Table S1) were extracted
based on correlations among the observed biomarkers
(eigenvalues > 1). In an EFA, the names of the factors
are given by the researchers after carefully examining
what is common between the observed variables/bio-
markers that have high loadings (correlation equivalent)
on each factor.
Factor 1 (carotenoids) had high factor loadings (> 0.30)
of carotenoids including α-carotene, β-carotene,
β-cryptoxanthin, lutein, and zeaxanthin. Factor 2 (other
nutrients) had high loadings of selenium, vitamin B6,
vitamin E (α-tocopherol), lycopene, α-carotene, and
β-cryptoxanthin (the last three are carotenoids as well).
Factor 3 (inflammation) had high loadings of C-reactive
protein (CRP), soluble CD14 (sCD14), interleukin 18
(IL-18), and ferritin (an indicator of iron stores but also
an acute phase protein) (Additional file 1: Table S1). As
is common in factor analysis, some biomarkers (e.g.,
vitamin D) did not have high loadings in any of the three
extracted factors.
Higher scores of the carotenoids and other nutrients
factors were associated with reduced hazards of CTF in
univariable models, but not in multivariable models that
Table 1 Characteristics of population by CTF cases and
control status
Characteristic All
n = 290
CTF
n = 124 (43%)
Controls
n = 166 (57%)
p valuea
Gender
Male 160 (55) 71 (44) 89 (56) 0.55
Female 130 (45) 53 (41) 77 (59)
Age (years) 35.0
(29.0–42.0)
35.5
(29.5–42.0)
35.0
(29.0–42.0)
0.81
Country
Brazil 44 (15) 16 (36) 28 (64) 0.001
Haiti 34 (12) 11 (32) 23 (68)
India 23 (8) 18 (78) 5 (22)
Malawi 38 (13) 22 (58) 16 (42)
Peru 19 (7) 4 (21) 15 (79)
South Africa 38 (13) 20 (53) 18 (47)
Thailand 23 (8) 6 (26) 17 (74)
USA 44 (15) 17 (39) 27 (61)
Zimbabwe 27 (9) 10 (37) 17 (63)
Body mass index (kg/m2)
< 18.5 29 (10) 18 (62) 11 (38) 0.001
18–25 192 (66) 89 (46) 103 (54)
≥ 25 69 (24) 17 (25) 52 (75)
Prior TB diagnosis
Yes 59 (20) 34 (58) 25 (42) 0.01
No 231 (80) 90 (39) 141 (61)
Treatment arm
A 100 (35) 58 (56) 45 (44) 0.72
B 108 (37) 54 (42) 39 (58)
C 82 (28) 67 (29) 27 (71)
CD4 count (cells/mm3)
< 100 103 (36) 50 (69) 22 (31) < 0.001
100–200 93 (32) 45 (49) 46 (51)
> 200 94 (34) 43 (41) 63 (59)
Log viral load (copies/mL)
< 4 21 (7) 6 (29) 15 (71) 0.18
4–5 98 (34) 38 (39) 60 (61)
> 5 171 (59) 80 (47) 91 (53)
Hypoalbuminemia
Yes (≤ 3.5 g/dL) 77 (19) 51 (41) 26 (16) < 0.001
No (> 3.5 g/dL) 215 (81) 73 (59) 140 (84)
Anemia
Yes 168 (58) 87 (54) 81 (46) < 0.001
No 121 (42) 36 (50) 85 (50)
Data are presented as number (%) of the CTF case control. Anemia is defined
based on hemoglobin cutoffs for males (< 13.0 g/dL) and non-pregnant females
(< 12.0 g/dL). aFisher’s exact test was used to calculate the p values for categorical
variables, and the rank sum test for continuous variables
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adjusted for sex, age, country, BMI, baseline TB status,
CD4 count, viral load, treatment arm, anemia, and hypo-
albuminemia (Table 2). In contrast, higher scores of in-
flammation factor were associated with increased
hazards of CTF in both univariable (hazard ratio (HR)
1.53; 95% confidence interval (CI) 1.32–1.77) and multi-
variable (adjusted HR (aHR) 1.47; 95% CI 1.17–1.84)
analyses (Table 2).
As CTF is a composite diagnosis that includes multiple
outcomes with a range in severity, we also assessed
whether similar patterns were observed when we limited
our analysis to more severe outcomes. In the severe out-
come case-control population, cases and controls differed
significantly by the following baseline characteristics:
country (p = 0.01), BMI (p = 0.003), prior TB (p = 0.02),
CD4 count, hypoalbuminemia, and anemia (all p < 0.001)
(data not shown). For this severe outcome analysis, three
factors were extracted based on the EFA (eigenvalues > 1).
The factors extracted in this analysis had a remark-
ably similar profile to our prior analysis where CTF
was the outcome (Additional file 2: Table S2). Factor 1 (ca-
rotenoids) and factor 2 (other nutrients) had high loadings
of the same markers, while factor 3 (inflammation) had an
additional marker with high loading (IP-10) (Additional file 2:
Table S2). Similar to our analysis with CTF, higher scores of
the carotenoids and other nutrients factor were associated
with reduced hazards of severe outcomes in univariable but
not multivariable models (Table 3). In contrast, higher
scores of the inflammation factor had increased hazards of
severe outcomes only in multivariable models (aHR 1.60;
95% CI 1.24–2.06) (Table 3).
In addition to severe outcomes, we also conducted
a virologic failure case-control analysis. The factor
profiles were very similar to those of the CTF and se-
vere outcomes analysis, where three factors were ex-
tracted and had the same high loading markers
(Additional file 3: Table S3). As with the CTF ana-
lysis, higher scores of the inflammation factor (but
not the other two factors) were associated with in-
creased hazards of virologic failure in both univariable
(HR 1.32; 95% CI 1.11–1.56) and multivariable models
(aHR 1.36; 95% CI 1.05–1.75) (Additional file 4: Table S4).
EFA and association with incident active TB
In the incident active TB case-control population, cases and
controls differed significantly by the following baseline
characteristics: BMI (p = 0.001), prior TB (p = 0.02), CD4
count (p = 0.02), country, hypoalbuminemia, and anemia
(all p < 0.001) (data not shown). The EFA analysis of base-
line biomarkers in the incident active TB case-control ana-
lysis also yielded three factors (eigenvalues > 1). However,
the profiles of the factors and their association with inci-
dent active TB had some important differences from the
CTF analyses (Additional file 5: Table S5). In this analysis,
factor 1 (high carotenoids and low IL-18) had high loadings
of α-carotene, β-carotene, β-cryptoxanthin, lutein, and zea-
xanthin, as well as high negative loadings of IL-18, ferritin,
and γ-tocopherol. Factor 2 (other nutrients) had high load-
ings of selenium, vitamin A (retinol), vitamin B6, vitamin E
(α-tocopherol), lycopene, α-carotene, and β-cryptoxanthin.
Factor 3 (inflammation) had high loadings of IFN-γ, TNF-α,
IL-6 and IP-10 (Additional file 5: Table S5).
Interestingly, higher scores of factor 1 (high carotenoids
and low IL-18) were associated with reduced hazards of TB
incidence in both univariable (HR 0.56; 95% CI 0.37–0.82)
and multivariable analyses (aHR 0.48; 95% CI 0.26–0.87)
(Table 4). Higher scores of factor 2 (other nutrients) were
associated with reduced hazards of TB incidence in univari-
able but not in multivariable models. Unlike the results
with CTF, factor 3 (inflammation) was not associated with
increased hazards of incident active TB in both univariable
(HR 1.15; 95% CI 0.83–1.54) and multivariable models
(aHR 0.91; 95% CI 0.57–1.45) (Table 4).
Table 2 Association of each factor with clinical treatment failure
Univariable analysis
HR (95% CI)
Multivariable analysis
HR (95% CI)
Factor 1 (Carotenoids) 0.71 (0.56–0.90) 0.77 (0.57–1.05)
Factor 2 (Other nutrients) 0.79 (0.63–0.87) 0.83 (0.57–1.32)
Factor 3 (Inflammation) 1.53 (1.32–1.77) 1.47 (1.17–1.84)
The association of each factor with CTF was determined in univariable and
multivariable Cox regression models. Sex, age, country, treatment arm, body
mass index (BMI), baseline TB status, CD4 count, viral load, anemia, and
hypoalbuminemia were adjusted for in the multivariable models. N = 290
(124 cases, 166 controls)
Table 3 Association of each factor with severe outcomes
Univariable analysis
HR (95% CI)
Multivariable analysis
HR (95% CI)
Factor 1 (Carotenoids) 0.71 (0.52–0.95) 0.86 (0.58–1.26)
Factor 2 (Other nutrients) 0.75 (0.57–0.98) 0.78 (0.49–1.26)
Factor 3 (Inflammation) 0.97 (0.61–1.53) 1.60 (1.24–2.06)
The association of each factor with severe outcomes was determined in
univariable and multivariable Cox regression models. Sex, age, country,
treatment arm, body mass index (BMI), baseline TB status, CD4 count, viral
load, anemia, and hypoalbuminemia were adjusted for in the multivariable
models. Severe outcomes were defined as death, serious bacterial infections/
sepsis, and opportunistic infections. N = 254 (81 cases, 173 controls)
Table 4 Association of each factor with incident active TB
Univariable analysis
HR (95% CI)
Multivariable analysis
HR (95% CI)
Factor 1 (High carotenoids
and low IL-18)
0.56 (0.38–0.82) 0.48 (0.26–0.87)
Factor 2 (Other nutrients) 0.65 (0.45–0.95) 0.98 (0.48–2.05)
Factor 3 (Inflammation) 1.15 (0.83–1.54) 0.91 (0.57–1.45)
The association of each factor with incident active TB was determined in
univariable and multivariable Cox regression models. Baseline variables
including sex, age, country, treatment arm, body mass index (BMI), CD4 count,
viral load, baseline TB status, anemia, and hypoalbuminemia were adjusted for
in the multivariable models. N = 220 (47 cases, 173 controls)
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Sensitivity analyses
Although incident active TB meets the definition for
both CTF and severe outcomes, the inclusion of TB as
an element of these outcomes (CTF and severe out-
comes) could potentially affect the derivation of the fac-
tors and association of the factor with the outcomes. As
a result, we have conducted sensitivity analyses that
remove incident active TB from the CTF (N = 242) and
severe outcome (N = 208) analyses. The factor profiles
were similar, and the results are consistent with the ori-
ginal analysis for the both the CTF (aHR 1.50; 95% CI
1.15–1.98 for factor 3) and severe outcomes (aHR 1.95;
95% CI 1.35–2.82 for factor 3) analysis (data not shown).
Our case-control analysis of incident active TB included
individuals with prevalent TB at baseline (pre-ART initi-
ation). In a sensitivity analysis removing those with prevalent
TB at baseline, the profile of factors remained similar, and
our results were consistent (aHR 0.46; 95% CI 0.23–0.91 for
factor 1) (data not shown).
Discussion
In our study of HIV-infected individuals initiating ART,
underlying factors were extracted from multiple biomarkers
of baseline nutritional and immunological status, and the
association of these factors with adverse HIV outcomes
(CTF and incident active TB) was assessed. Higher scores
of the inflammation factor were associated with increased
hazards of CTF. Interestingly, higher scores of the high
carotenoids and low IL-18 factor were associated with
reduced hazards of incident active TB. Our results, utilizing
analytical approaches that account for correlations (e.g.,
EFA) between multiple biomarkers, support findings from
other studies on the association of inflammation and
micronutrients with HIV outcomes, while suggesting that it
may be valuable to focus on potential interventions that
address the underlying factor rather than any one
particular biomarker.
In the CTF analysis, when we assessed the relationship
of each factor with outcome, only the inflammation fac-
tor was associated with increased hazards of CTF. There
is increasing evidence of inflammation being associated
with adverse HIV outcomes, and the high loading
markers including IL-18, CRP, and sCD14 have all been
individually associated with adverse HIV outcomes in
studies including those from this cohort [1–6]. Although
using factors, based on measurement of multiple bio-
markers, to risk stratify individuals is not practical in a
clinical setting when compared to single markers that
are also predictive, our results can inform interventions
that seek to reduce inflammation. The utility of such an
approach can be seen in assessment of food insecurity,
where responses from multiple questions are reduced to
a single variable (although not through EFA) of food in-
security, which has shown to be associated with various
adverse health outcomes in HIV [29–31] and is a target
for intervention [32]. While confirming the important
role of these specific cytokines, our results also suggest
that a more effective approach to reduce adverse HIV
outcomes might be to focus on interventions that reduce
the underlying inflammation (factor) represented by
various correlated markers rather than focusing on only
one of the markers which might represent a more spe-
cific type of inflammation (e.g., sCD14 for monocyte
activation).
Notably the extracted factors in the incident active TB
analyses were distinct from those in the CTF analyses.
Factor 1 comprised high carotenoids and low IL-18, and
the inflammation factor had high loadings of IFN-γ,
TNF-α, IL-6, and IP-10. A major reason for the profiles
of the factors being different between the CTF and TB
case-control analyses is that the outcomes are different
(TB accounts for 31% of the cases in CTF; 100% in TB
case control). The relationship between carotenoids and
IL-18 is intriguing, and some studies have shown that
IL-18 levels can be affected by β-carotene metabolism
[33, 34].
In our association studies, only the high carotenoids
and low IL-18 factors were associated with reduced haz-
ards of incident active TB. Given the findings that
over-activation of inflammation (e.g., type I IFNs) results
in increased incidence of TB [35], it is biologically plaus-
ible that inflammasome activation and increase in IL-18
could also result in higher incident TB [36]. The poten-
tial protective relationship of carotenoids with incident
TB warrants further investigations, but potential mecha-
nisms include an effect on immunity (e.g., inflammation,
macrophage function, mucosal immunity) and oxidative
stress [37–40]. Plasma carotenoids are considered a bio-
marker of fruit and vegetable intake [41, 42], and prior
studies have observed that higher intakes of fruits and
vegetables are protective against risk of TB [43, 44]. A
new study from HIV-uninfected individuals [45] also
suggests that low carotenoid levels might be associated
with increased risk of TB.
The inflammation factor was not associated with devel-
opment of incident active TB. A closer look at the high
loading biomarkers (IFN-γ, TNF-α, IL-6, IP-10) suggests
that while they are also pro-inflammatory, they have a
different profile from the ones that load highly in the CTF
inflammation factor (sCD14, CRP, IL-18, ferritin). The high
loading biomarkers in the incident active TB inflammation
factor are the classical Th1 cytokines important in anti-TB
immunity [35], and they have not been consistently associ-
ated with adverse outcomes in HIV.
In our prior analyses on the association of an individual
marker with an outcome (CTF or TB) using this same
dataset [6, 7, 46], specific markers that were independently
associated (e.g., vitamin D) with the outcome do not have
Shivakoti et al. BMC Medicine  (2018) 16:161 Page 6 of 9
significant loadings on any of the dominant factors. How-
ever, it is important to note that it is possible for a specific
marker to still be independently associated with an out-
come despite not being a part of one of the extracted
factors. Factors are chosen based on correlations between
the observed variables and are independent of the out-
come; thus, the individual marker might or might not
strongly load into any of the extracted factors. Future
studies should test whether interventions that target the
individual marker (e.g., vitamin D) and/or the underlying
factor (e.g., inflammation) may improve clinical outcomes.
Examples of potential therapeutics that may affect the
underlying factor include diet (e.g., high-carotenoid foods
or supplements for TB) and probiotics (to reduce micro-
bial translocation and immune activation), along with
medications to reduce inflammation (e.g., statins and as-
pirin) and treat co-morbidities (e.g., cytomegalovirus and
helminth infections). Future studies will need to address
how these interventions will affect the factors and ultim-
ately HIV and TB outcomes.
The strengths of our study include the assessment of
exposure prior to the outcome, the assessment of mul-
tiple outcomes, and addressing potential collinearity be-
tween multiple correlated biomarkers by using EFA. A
limitation of this study is the CTF definition for the pri-
mary outcome, which is a composite definition based on
multiple outcomes ranging from death to less severe
outcomes. While this is based on a WHO definition that
is widely used, we conducted a secondary analysis with
more severe outcomes as well as virologic failure and
observed a similar pattern. In this study, we are also un-
able to distinguish between TB recently acquired
through transmission, TB reactivation, and subclinical/
unmasked TB. The parent study was not designed to
distinguish between TB reactivation and TB recently ac-
quired through transmission. About 30% of the incident
active TB cases developed within 3 months of ART initi-
ation, which suggests that they might be subclinical or
unmasked TB. However, we found a similar strength of
associations but were underpowered to reach statistical
significance at the p < 0.05 level when focusing our ana-
lyses only on new TB cases occurring after 3 months
post-ART initiation. Another limitation of our study is
that we did not assess food insecurity. Given the litera-
ture on the association of food insecurity with adverse
HIV outcomes [29–31] along with its link to nutrition
and immunity [47], a better understanding of the rela-
tionship between the extracted factors and food insecur-
ity may have provided further insight into potential
interventions.
Conclusion
In conclusion, our results suggest that groupings of nu-
tritional and immunological biomarkers underlying
specific factors are associated with adverse events and
that an approach focusing on interventions targeting the
underlying factor rather than any single observed vari-
able warrants investigation. In addition, our results focus
on a group of inflammatory biomarkers that further con-
firm the central role of inflammation in adverse HIV
outcomes, while also suggesting that carotenoids poten-
tially protect against TB.
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